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Abstract 
Lobular carcinoma in situ is a form of in situ neoplasia that develops within the terminal 
lobules of the breast. It is an extremely rare finding in males due to the lack of lobular de-
velopment in the male breast. The authors herein report an unusual case of incidentally 
discovered lobular carcinoma in situ in a male patient with recurrent bilateral gynecomastia 
who was subsequently diagnosed with invasive ductal carcinoma of the left breast. The pa-
thology of lobular carcinoma in situ in a male as well as screening MRI surveillance of male 
patients at high risk for breast cancer are discussed, emphasizing the importance of screening 
and imaging follow up in men who are at high risk for breast cancer. 
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Introduction 
Lobular carcinoma in situ (LCIS) is a form of in 
situ neoplasia that develops within the terminal lob-
ules of the breast. It is extremely rare in males due to 
the lack of lobular development in the male breast. 
Furthermore,  there  is  scarce  data  on  the  utility  of 
screening MRI for male patients who are known to 
have high risk lesions. 
We herein report a rare case of LCIS in a male 
breast discovered incidentally on pathologic analysis 
of the breast tissue, which had been removed during 
breast reduction surgery for gynecomastia. Invasive 
ductal carcinoma developed in the ipsilateral breast 
two years later, as was detected on screening MRI. 
Case Report 
The  patient  is  a  55-year-old  African  American 
male who reported a brief history of anabolic steroid 
use and no family history of breast cancer. The patient 
had a history of multiple surgical procedures for re-
current gynecomastia over the course of many years. 
The patient presented to our institution for bilateral 
breast  reduction  for  cosmetic  purposes.  Pathologic 
evaluation demonstrated a few foci of LCIS within the 
left breast along with atypical duct cell hyperplasia in 
a  background  of  gynecomastia.  Due  to  the  highly 
unusual finding of LCIS in this male patient, genetic 
analysis  was  performed  and  the  male  XY  genotype 
was confirmed.  
The  patient  was  subsequently  referred  to  our 
breast imaging center for a screening bilateral breast 
MRI.  This  demonstrated  mild  diffuse  background 
enhancement  bilaterally  without  suspicious  enhanc-
ing  signal  abnormalities  in  either  breast.  Screening 
annual breast MRI was recommended in view of his 
highly unusual diagnosis of LCIS. 
Screening  MRI  of  both  breasts  performed  15 
months later demonstrated interval development of a 
1.1 cm enhancing ill-defined mass at the 1 o'clock axis 
of  the  left  breast  (Figure  1).  A  corresponding  solid 
hypoechoic mass with angulated margins was seen on 
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targeted left breast ultrasound (Figure 2). Mammog-
raphy  demonstrated  heterogeneously  dense  breast 
tissue  with  post  surgical  changes  bilaterally.  No 
dominant mass or suspicious clustered microcalcifi-
cations were identified in either breast (Figure 3). Ul-
trasound guided core biopsy yielded moderately dif-
ferentiated invasive ductal carcinoma.  
 
 
Figure 1. MR image demonstrating a 1.1 cm suspicious enhancing 
mass  at  the  left breast 1 o'clock  axis  for which  target-
ed ultrasound was recommended. 
 
 
Figure 2. Targeted ultrasound of the left breast demonstrating a 
solid hypoechoic lesion at the 1 o'clock axis which corresponded 
to the enhancing lesion on the MRI. 
 
Figure  3.  Digital bilateral mammogram demonstrating hetero-
geneously dense breast tissue and post surgical changes bilaterally. 
A microclip is seen at the 1 o'clock axis of the left breast, marking 
the site of ultrasound guided core biopsy. 
 
 
The patient was referred for surgical evaluation. 
Physical exam at that time revealed that his gyneco-
mastia  had  recurred  and  the  patient  was  noted  to 
have C-cup sized breasts. He had significant hyper-
trophic  circumareolar  and  inframammary  scars  on 
both breasts from his previous breast surgeries. BRCA 
testing  was  negative.  Bilateral  mastectomies  were 
performed.  
Pathology 
The breast reduction specimen consisted of 426 
grams of tissue from the right breast and 490 grams of 
tissue from the left breast. Gross examination revealed 
80% fibrous tissue and 20% adipose tissue without a 
discrete mass. Extensive histopathologic sampling of 
the left breast revealed a few foci of lobular carcinoma 
in  situ  which  was  confirmed  with  a  negative 
E-cadherin immunostain (Figures 4 and 5). Atypical 
duct cell hyperplasia, cribriform and micropapillary 
type was also present in a few foci on the left (Figure 
6). Both right and left breasts revealed gynecomastia, 
florid phase. 
The  ultrasound  guided  core  biopsy  specimen 
demonstrated invasive ductal carcinoma and subse-
quent bilateral mastectomy specimens revealed a 1.4 x 
1.2 x 1.0 cm irregular hard mass at the 1 o’clock posi-
tion of the left breast. No discrete mass was seen in the 
right  mastectomy  specimen.  The  breast  tissue  was 
about 60% fibrous bilaterally. Histopathologic exam-
ination of the left breast mass revealed a 1.3 cm well 
differentiated invasive ductal cancer with a Notting-
ham Score of 5 of 9, including a tubule score of 2, nu-
clear pleomorphism score of 2 and mitotic count score 
of 1 (Figure 7). The carcinoma was strongly and dif- Journal of Cancer 2012, 3 
 
http://www.jcancer.org 
228 
fusely  positive  for  both  estrogen  and  progesterone 
receptors and negative for Her-2/Neu. Lobular car-
cinoma in situ was present bilaterally as was florid 
phase  gynecomastia.  Sentinel  lymph  nodes  were 
negative. 
 
 
Figure 4. Monotonous small cells of lobular carcinoma in situ (thin arrows) show pagetoid extension along ducts with undermining of 
normal ductal epithelium (thick arrow). 
 
 
 
 
Figure 5. E-cadherin immunostain shows absence of staining in cells of lobular carcinoma in situ (thin arrows) with positive staining in 
residual benign ductal cells (thick arrow).  Journal of Cancer 2012, 3 
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Figure 6. Atypical ductal hyperplasia showing hyperchromatic cells with micropapillary type. 
 
 
Figure 7. Invasive ductal carcinoma showing a mixture of infiltrating tubules and cords of cells. 
 
Discussion 
Breast carcinoma in men is an uncommon dis-
ease,  representing  approximately  1%  of  all  breast 
cancers and 1% of all malignancies in men; although 
based  on  current  statistics,  the  incidence  of  male 
breast cancer is increasing (1,2). While the etiology of 
male breast cancer is uncertain, risk factors include 
genetic  predisposition,  prior  radiation  exposure,  al-
terations  of  the  estrogen-testosterone  ratio,  and  oc-
cupational hazards (3). To date, there is no evidence 
linking gynecomastia with male breast cancer (4,5).  
Male breast cancers are predominantly of ductal 
origin due to the lack of terminal lobules within the 
male breast. As a result, LCIS and infiltrating lobular 
carcinoma are extremely unusual in male patients (6). 
Nance et al reported the first case of LCIS in a phe-
notypic  and  apparently  genotypic  male  in  1989  in 
association with a large infiltrating lobular carcinoma 
(7); and in fact, only a limited number of cases of in- Journal of Cancer 2012, 3 
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filtrating lobular carcinoma of the male breast have 
been reported (8).  
Over the past decade, there has been an increase 
in the number of imaging studies performed in male 
patients. These are largely performed in patients who 
present  with  complaints  of  a  breast  lump  and/or 
breast pain. Although there are no standardized pro-
tocols in evaluating the male breast, mammography is 
usually the initial study and is followed by ultrasound 
as needed (9). Occasionally, MRI may be obtained for 
further  evaluation,  and  it  has  been  shown  that  the 
diagnostic criteria used in the evaluation of the female 
breast may be applied to the male breast as well (10). 
However, there are no guidelines regarding screening 
mammography in asymptomatic men at any age due 
to the rarity of male breast cancer. In the absence of 
screening,  most  male  patients  present  with  clinical 
symptoms and more advanced disease (11). Current 
National Comprehensive Cancer Network guidelines 
for men with BRCA mutations recommend consider-
ation of baseline mammography followed by annual 
mammography in those men who are shown to have 
gynecomastia on the baseline study (12).  
The  role  of  screening  MRI  even  in  female  pa-
tients with LCIS is not well established despite the fact 
that LCIS is known to represent a high risk marker 
lesion. In fact, lifetime risk estimates for patients with 
incidentally  diagnosed  LCIS  range  from  10  to  20%, 
imparting a significant lifetime risk for the develop-
ment of invasive ductal or lobular carcinoma in either 
breast (13,14). In 2007, a retrospective study evaluated 
screening MRI in asymptomatic female patients with 
LCIS, demonstrating a small increase in early cancer 
detection  (15).  Subsequently,  the  2007  American 
Cancer  Society  guidelines  for  screening  breast  MRI 
advised  that  there  was  insufficient  evidence  to  rec-
ommend for or against screening MRI in patients with 
a known diagnosis of LCIS and only recommended 
annual screening breast MRI for patients with a life-
time risk of greater than 20-25% (16). The 2009 Na-
tional  Comprehensive  Cancer  Network  guidelines, 
however, advised consideration of annual breast MR 
imaging as an adjunct to mammography and clinical 
examination in these patients (17). More recently, two 
additional  retrospective  studies  specifically  studied 
screening breast MRI in asymptomatic female patients 
with LCIS and concluded that screening breast MRI is 
a useful adjunctive tool to mammography in this high 
risk population (18,19). As such, one may extrapolate 
this information to males with a known diagnosis of 
LCIS and recommend screening MRI, as was done in 
this case. 
This case report is, to the best of our knowledge, 
the first reported case of a genotypic and phenotypic 
male  patient  without  a  BRCA  mutation,  who  was 
found to have incidental LCIS which was unrelated to 
a lobular carcinoma. In addition, this is the first re-
ported case of a male patient with LCIS to be screened 
with annual MRI surveillance and in whom the MRI 
detected a mammographically occult stage I invasive 
ductal carcinoma. This case highlights the importance 
of imaging management and the potential for an im-
proved  prognosis  in  men  who  are  at  high  risk  for 
breast cancer. 
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